Advertisement

Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma

  • Wolfgang Lamm
  • Barbara Kiesewetter
  • Hannah Puhr
  • Werner Dolak
  • Marius E. Mayerhöfer
  • Markus Raderer
Letter to the Editor
  • 67 Downloads

Dear Editor,

Mantle cell lymphoma (MCL) is an aggressive subtype of B cell non-Hodgkin’s lymphoma (NHL) which accounts for approximately 6% of all NHLs [1]. Roughly 5% of patients suffer from the more aggressive blastic variant MCL [2].

Bendamustine in combination with rituximab (RB) has shown promising results in different phase III trials in elderly patients unfit for high-dose chemotherapy in different kinds of lymphomas, including MCL with response rates of approximately 86–93% [3, 4, 5, 6].

Bendamustine in relapsed/refractory lymphomas including MCL also showed promising results [7]. RB retreatment, however, has never been investigated before. In view of this, we have performed a retrospective single-center analysis to evaluate the clinical efficacy and safety of RB retreatment in patients with MCL.

Seven patients were retreated with RB (Table 1), which was given on a 3-week basis along with dexamethasone. The median age was 81 years (range 65–83). Additional patients’...

Notes

Compliance with ethical standards

All authors gave their informed consent for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Barista I, Romaguera JE, Cabanillas F (2001) Mantle-cell lymphoma. The Lancet Oncology 2:141–148CrossRefGoogle Scholar
  2. 2.
    Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 15:1785–1791CrossRefGoogle Scholar
  3. 3.
    Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Study group indolent L: Bendamustine plus rituximab versus chop plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210CrossRefGoogle Scholar
  4. 4.
    Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or r-chop/r-cvp in first-line treatment of indolent nhl or mcl: the bright study. Blood 123:2944–2952CrossRefGoogle Scholar
  5. 5.
    Becker M, Tschechne B, Reeb M, Schwinger U, Bruch HR, Frank M, Strassl L (2015) Bendamustine as first-line treatment in patients with advanced indolent non-hodgkin lymphoma and mantle cell lymphoma in german routine clinical practice. Ann Hematol 94:1553–1558CrossRefGoogle Scholar
  6. 6.
    Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K (2017) Japanese Bendamustine Lymphoma Study G: bendamustine plus rituximab for previously untreated patients with indolent b-cell non-hodgkin lymphoma or mantle cell lymphoma: a multicenter phase ii clinical trial in Japan. Int J Hematol 105:470–477CrossRefGoogle Scholar
  7. 7.
    Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J (2016) Study Group Indolent L: Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology 17:57–66CrossRefGoogle Scholar
  8. 8.
    Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH (2015) Phase ii study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol 94:2025–2032CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Wolfgang Lamm
    • 1
  • Barbara Kiesewetter
    • 1
  • Hannah Puhr
    • 1
  • Werner Dolak
    • 2
  • Marius E. Mayerhöfer
    • 3
  • Markus Raderer
    • 1
  1. 1.Department of Medicine I, Clinical Division of OncologyMedical University of ViennaViennaAustria
  2. 2.Department of Medicine III, Clinical Division of Gastroenterology and HepatologyMedical University of ViennaViennaAustria
  3. 3.Department of Biomedical Imaging and Image-guided TherapyMedical University of ViennaViennaAustria

Personalised recommendations